Sophie Lebel

Dr. Sophie Lebel

School of Psychology, University of Ottawa, Ottawa, ON K1N 6N5, Canada

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2016 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
OAon behalf of the University of Ottawa Fear of Cancer Recurrence Colloquium attendees
on behalf of the University of Ottawa Fear of Cancer Recurrence Colloquium attendees
Sophie LebelSophie Lebel
Sophie Lebel
Gozde OzakinciGozde Ozakinci
Gozde Ozakinci
Gerald HumphrisGerald Humphris
Gerald Humphris
BMBrittany Mutsaers
Brittany Mutsaers
PBPhyllis Butow
Phyllis Butow

7 April 2022 in Psycho-Oncology
Verified
Journal Article
Open access
YLYvonne L. Luigjes‐Huizer
Yvonne L. Luigjes‐Huizer
NTNina M. Tauber
Nina M. Tauber
Gerald HumphrisGerald Humphris
Gerald Humphris
NKNadine Kasparian
Nadine Kasparian
WLWendy W. T. Lam
Wendy W. T. Lam
MLMarije L. van der Lee
Marije L. van der Lee
Objective: Care for fear of cancer recurrence (FCR) is considered the most common unmet need among cancer survivors. Yet the prevalence of FCR and predisposing factors remain inconclusive. To support targeted care, we provide a comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI‐SF). We also report on associations between FCR and clinical and demographic characteristics.Methods: This is a systematic review and individual participant data (IPD) meta‐analysis on the prevalence of FCR. In the review, we included all studies that used the FCRI‐SF with adult (≥18 years) cancer survivors and patients. Date of search: 7 February 2020. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool.Results: IPD were requested from 87 unique studies and provided for 46 studies comprising 11,226 participants from 13 countries. 9311 respondents were included for the main analyses. On the FCRI‐SF (range 0–36), 58.8% of respondents scored ≥13, 45.1% scored ≥16 and 19.2% scored ≥22. FCR decreased with age and women reported more FCR than men. FCR was found across cancer types and continents and for all time periods since cancer diagnosis.Conclusions: FCR affects a considerable number of cancer survivors and patients. It is therefore important that healthcare providers discuss this issue with their patients and provide treatment when needed. Further research is needed to investigate how best to prevent and treat FCR and to identify other factors associated with FCR.The protocol was prospectively registered (PROSPERO CRD42020142185).

27 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Sophie LebelSophie Lebel
Sophie Lebel
BMBrittany Mutsaers
Brittany Mutsaers
CTChristina Tomei
Christina Tomei
CLCaroline Séguin Leclair
Caroline Séguin Leclair
GJGeorden Jones
Georden Jones
ADAndreas Dinkel
Andreas Dinkel
Patients with chronic diseases commonly report fears of illness or symptoms recurring or worsening. These fears have been addressed from an illness-specific perspective (e.g., fear of cancer recurrence), a generic illness perspective (e.g., fear of progression), and a psychiatric perspective (DSM-5 illness anxiety disorder and somatic symptom disorder). The broader concept of health anxiety (HA) can also be applied to patients with a chronic disease. This review was conducted to investigate the conceptual, theoretical, measurement-overlap, and differences between these distinct perspectives. We also aimed to summarize prevalence, course, and correlates of these fears in different chronic illnesses. We used PsycINFO, PubMED, CINAHL, Web of Science, SCOPUS, and PSYNDEX to conduct a systematic review of studies pertaining to these fears in chronic illness published from January 1996 to October 2017. A total of 401 articles were retained. There were commonalities across different conceptualizations and diseases: a high prevalence of clinical levels of fears (>20%), a stable course over time, and a deleterious impact on quality of life. Reviewed studies used definitions, models, and measures that were illness-specific, with only a minority employing a psychiatric perspective, limiting cross-disease generalizability. There appears to be some applicability of DSM-5 disorders to the experience of fear of illness/symptoms in patients with a chronic illness. While conceptualizing HA on a continuum ranging from mild and transient to severe may be appropriate, there is a lack of agreement about when the level of fear becomes ‘excessive.’ The definitions, models, and measures of HA across chronic illnesses involve affective, cognitive, behavioral, and perceptual features. The concept of HA may offer a unifying conceptual perspective on the fears of illness/symptoms worsening or returning commonly experienced by those with chronic disease.

27 December 2012 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
Sophie LebelSophie Lebel
Sophie Lebel
CTChristina Tomei
Christina Tomei
AFAndrea Feldstain
Andrea Feldstain
SBSara Beattie
Sara Beattie
MMMegan McCallum
Megan McCallum

16 October 2008 in Future Oncology
Verified
Journal Article
Closed access
Sophie LebelSophie Lebel
Sophie Lebel
GDGerald M Devins
Gerald M Devins
The purpose of the present review is to examine stigma and its consequences among people with cancer, with an emphasis on the situation in which one's behavior may have contributed to the disease. We examine whether voluntarily engaging in behavior that adds to cancer risk leads to increased stigma after cancer onset, as compared with when one's behavior is not considered (by the affected individual or by others) to have contributed to the onset of cancer. We conducted literature searches in PsychInfo and Medline and identified 38 published papers that empirically addressed cancer-related stigma. We found evidence of increased negative attitudes and more severe consequences of stigma among people that have engaged in a behavior that is perceived to have contributed to their cancer, compared with those who are not perceived to have contributed to their disease.

11 November 2019 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
BMBrittany Mutsaers
Brittany Mutsaers
PBPhyllis Butow
Phyllis Butow
ADAndreas Dinkel
Andreas Dinkel
Gerald HumphrisGerald Humphris
Gerald Humphris
Christine MaheuChristine Maheu
Christine Maheu
Sophie LebelSophie Lebel
Sophie Lebel